PL2590992T3 - Agoniści receptorów opioidowych mu będące analogami endomorfin - Google Patents

Agoniści receptorów opioidowych mu będące analogami endomorfin

Info

Publication number
PL2590992T3
PL2590992T3 PL11804387T PL11804387T PL2590992T3 PL 2590992 T3 PL2590992 T3 PL 2590992T3 PL 11804387 T PL11804387 T PL 11804387T PL 11804387 T PL11804387 T PL 11804387T PL 2590992 T3 PL2590992 T3 PL 2590992T3
Authority
PL
Poland
Prior art keywords
endomorphins
receptor agonist
opioid receptor
agonist analogs
analogs
Prior art date
Application number
PL11804387T
Other languages
English (en)
Inventor
James E. Zadina
Laszlo Hackler
Original Assignee
The Administrators Of The Tulane Educational Fund
United States Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2590992(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Administrators Of The Tulane Educational Fund, United States Department Of Veterans Affairs filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL2590992T3 publication Critical patent/PL2590992T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486Analgesics, e.g. opiates, aspirine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
PL11804387T 2010-07-09 2011-07-08 Agoniści receptorów opioidowych mu będące analogami endomorfin PL2590992T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36303910P 2010-07-09 2010-07-09

Publications (1)

Publication Number Publication Date
PL2590992T3 true PL2590992T3 (pl) 2017-09-29

Family

ID=45441820

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11804387T PL2590992T3 (pl) 2010-07-09 2011-07-08 Agoniści receptorów opioidowych mu będące analogami endomorfin

Country Status (13)

Country Link
US (3) US8716436B2 (pl)
EP (2) EP2590992B1 (pl)
JP (2) JP6039553B2 (pl)
CA (1) CA2810170C (pl)
CY (1) CY1120618T1 (pl)
ES (1) ES2632787T3 (pl)
HR (1) HRP20171119T1 (pl)
HU (1) HUE033875T2 (pl)
PL (1) PL2590992T3 (pl)
PT (1) PT2590992T (pl)
RS (1) RS56129B1 (pl)
SI (1) SI2590992T1 (pl)
WO (1) WO2012006497A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20130178427A1 (en) * 2010-07-09 2013-07-11 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3710467A4 (en) * 2017-11-17 2021-08-04 Cytogel Pharma, LLC MU-OPIOID RECEPTOR POLYMERIC AGONISTS
CN111683654A (zh) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 新型镇痛药物制剂及其用途
US11578100B2 (en) 2018-03-28 2023-02-14 Florida Atlantic University Research Corporation Cyclic peptides, cyclic peptide conjugates and methods of use thereof
RU2687740C1 (ru) * 2018-11-26 2019-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Gly-His-Lys-Pro-Gly-Pro для достижения анальгетического эффекта при боли, вызванной температурным раздражением
EP3962928A4 (en) * 2019-05-03 2023-05-17 The Administrators of The Tulane Educational Fund METHODS OF TREATMENT OF OPIOID USE DISEASE
WO2023235232A2 (en) * 2022-05-31 2023-12-07 The Administrators Of The Tulane Educational Fund Glycosylated cyclic endomorphin analogs
CN116120402B (zh) * 2022-11-04 2024-03-15 深圳市维琪科技股份有限公司 一种环肽及其组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203496D0 (sv) * 1992-11-20 1992-11-20 Kabi Pharmacia Ab New oligopeptides
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
JP2006525942A (ja) 2002-12-23 2006-11-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トロンビン受容体アンタゴニストとしての新規なヘテロアリールペプチド模倣物
US7399762B2 (en) * 2005-04-25 2008-07-15 Research Triangle Institute Opioid receptor agonist compounds and their use in treatment of pain
US8809278B2 (en) * 2008-07-11 2014-08-19 University Of Kansas Cyclic tetrapeptides

Also Published As

Publication number Publication date
JP6279626B2 (ja) 2018-02-14
HUE033875T2 (en) 2018-01-29
EP3246333B1 (en) 2020-10-07
US8716436B2 (en) 2014-05-06
AU2011274522B2 (en) 2016-03-31
US20120322740A1 (en) 2012-12-20
AU2011274522A1 (en) 2013-02-07
HK1246811A1 (en) 2018-09-14
EP3246333A1 (en) 2017-11-22
EP2590992A2 (en) 2013-05-15
US20150315238A1 (en) 2015-11-05
RS56129B1 (sr) 2017-10-31
US20180222940A1 (en) 2018-08-09
CA2810170C (en) 2022-01-25
PT2590992T (pt) 2017-07-26
ES2632787T3 (es) 2017-09-15
CY1120618T1 (el) 2019-12-11
HRP20171119T1 (hr) 2017-10-06
EP2590992B1 (en) 2017-04-26
EP2590992A4 (en) 2013-12-18
CA2810170A1 (en) 2012-01-12
AU2011274522A8 (en) 2016-04-14
SI2590992T1 (sl) 2017-11-30
WO2012006497A2 (en) 2012-01-12
JP2013533890A (ja) 2013-08-29
JP2016084357A (ja) 2016-05-19
JP6039553B2 (ja) 2016-12-07
WO2012006497A3 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
PL2590992T3 (pl) Agoniści receptorów opioidowych mu będące analogami endomorfin
PL2619212T3 (pl) Analogi buprenorfiny działające agonistycznie i/lub antagonistycznie na receptory opioidowe
PT2927224T (pt) Antagonistas de receptores
GB2474748B (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
GB2470833A8 (en) Polycyclic antagonists of lysophosphatidic acid receptors.
LT2593452T (lt) Heterocikliniai junginiai, kaip ip receptoriaus agonistai
ZA201308702B (en) Antagonists of cb1 receptor
EP2483252A4 (en) COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
EP2462128A4 (en) COMPOUNDS AS LYSOPHOSPHATIDE ACID RECEPTOR ANAGONISTS
ZA201207292B (en) Cgrp receptor antagonist
ZA201306744B (en) Antagonists of the interleukin-1 receptor
ZA201305576B (en) Trpm8 receptor antagonists
IL232503A (en) H2 - Indazoles as antagonists of the ep2 receptor
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
IL235740A0 (en) Somatostatin receptor agonist formulations
EP2539706A4 (en) ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
ZA201301561B (en) 5-ht2b receptor antagonists
EP2618666A4 (en) NEW DIHYDROPYRIMIDIN-2 (1H) -ON COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
GB0922455D0 (en) Ep2 receptor antagonists